XML 15 R4.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data
 3 Months Ended 6 Months Ended 181 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Revenues:          
Collaboration and research and development revenue   $ 100   $ 100 $ 3,100
Product revenue 168 19 360 273 2,682
Grant revenue       16 3,648
Total revenue 168 119 360 389 9,430
Operating expenses:          
Cost of goods sold 72 92 178 234 1,570
Research and development 1,859 1,322 4,939 3,497 181,532
Selling, general and administrative 2,034 3,091 3,840 5,491 85,806
Goodwill and intangibles impairment         7,934
Restructuring costs         2,634
Total operating expenses 3,965 4,505 8,957 9,222 279,476
Operating loss (3,797) (4,386) (8,597) (8,833) (270,046)
Other income (expense):          
Costs associated with aborted 2004 IPO         (3,550)
Payment under guarantee         (1,652)
Change in valuation of derivative         (308)
Change in valuation of warrants 125 273 203 (516) 6,273
Warrant re-pricing         (44)
Foreign exchange (losses)/gains (19) (49) (87) (38) (4,342)
Interest income 13 8 24 17 13,704
Interest expense   (9)   (33) (4,677)
Total other income (expense) 119 223 140 (570) 5,404
Loss before taxes (3,678) (4,163) (8,457) (9,403) (264,642)
Income tax benefit 126 230 317 363 18,196
Net loss (3,552) (3,933) (8,140) (9,040) (246,446)
Dividends on preferred ordinary shares         (38,123)
Deemed dividend on convertible exchangeable preferred shares   (2,496)   (2,915) (3,515)
Dividend on convertible exchangeable preferred shares (182) (114) (364) (403) (3,293)
Net loss applicable to common shareholders $ (3,734) $ (6,543) $ (8,504) $ (12,358) $ (291,377)
Net loss per share- Basic and diluted $ (0.08) $ (0.18) $ (0.18) $ (0.36)  
Weighted average common shares outstanding 46,582,915 36,565,972 46,577,577 34,157,279